ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0556

Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response

Zachary Peters1, Lindsay Mendyka1, Sicong Shan1, Angelique Cortez1, William Rigby2, Christopher Burns1, Randolph Noelle3 and Sladjana Skopelja-Gardner1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth Hitchcock Medical Center, Lebanon, PA, 3Geisel School of Medicine at Dartmouth, Lebanon, NH

Meeting: ACR Convergence 2022

Keywords: Cutaneous, innate immunity, interferon, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Abstracts: Innate Immunity

Session Type: Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Most lupus patients chronically exhibit higher IFN-I scores in the skin, peripheral blood, and kidneys that is exacerbated by ultraviolet (UV) light. In normal skin, IFN-I response to UV returns to baseline over time, provoking the questions: what controls IFN-I response and why do cells in lupus skin fail to downregulate IFN-I production? Antibody-mediated activation of the immune checkpoint VISTA on monocytes suppresses their IFN-I signature and absence of VISTA enhances TLR7-stimulated IFNa production by pDCs. These findings prompted us to test the hypothesis that VISTA expression by keratinocytes regulates basal and UV light-triggered IFN-I production in the skin.

Methods: Skin biopsies from B6, B6.Vsir-/- (VISTA-deficient), KRT14creVsirfl/fl (Vsir-/- in keratinocytes), and cre-Vsirfl/fl female mice (3 mo) were collected prior to, 3 and 24h after UVB (500mJ/cm2). Gene expression was quantified by RNA-seq and pathway analysis performed (Rosalind). Skin infiltrating cells were quantified by flow cytometry. IFNb and IFNk levels were quantified by immunoblotting of skin lysates. Human keratinocytes were isolated from healthy skin and cultured in vitro. Cells were treated with agonistic anti-VISTA (803) or isotype IgG2a (20ug/ml) prior to UVB (50mJ/cm2), in the presence or absence of IFNa pre-treatment. Expression of IFN-Is, Vsir, and IFN-I stimulated genes (ISGs) were quantified by qPCR (4hr after UV) and IFN-I score derived.

Results: VISTA-deficient mice have a ~50-fold higher skin IFN-I score at baseline that is associated with greater IFNb protein levels. This increased IFN-I response in the absence of VISTA is not limited to the skin, as increased ISG expression was seen in the kidney. A single exposure of skin to UVB light resulted in a significantly higher IFN-I score in Vsir-/- vs. B6 skin 3 and 24hr after exposure, which was accompanied by significantly increased IFNb levels in the skin and blood. The higher IFN-I response in the absence of VISTA was not due to excess dead cells. While Vsir-/- mice demonstrated increased immune cell infiltration and chemokine production 24hr after UV, the elevated IFN-I score in the absence of VISTA was independent of immune cell influx at 3hr. RNA-seq analysis demonstrated suppressed DNA repair pathways in the absence of VISTA and upregulation of DNA sensing pathways ZBPI-STING and AIM2. The IFN-I score was also elevated in the skin of mice with conditional VISTA deletion (KRT14creVISTAfl/fl) both at baseline and 3hr after UV. Exposure of human primary keratinocytes to UVB light upregulated VISTA gene (4hr) and protein (24hr) expression. Pre-treatment of keratinocytes with an agonistic anti-VISTA IgG suppressed UV-induced IFNk and ISG expression. The suppressive effect of VISTA agonism on IFN-I response was maintained in keratinocytes with a pre-existing IFN-I signature.

Conclusion: These studies identify VISTA as a novel regulator of the IFN-I response and a potential therapeutic target to suppress IFN-I production in lupus skin and photosensitive reactions. The novel keratinocyte-intrinsic role of VISTA is particularly relevant to lupus pathogenesis as these cells demonstrate a high IFN-I signature, express high IFNk levels, and are direct targets of UVB rays.


Disclosures: Z. Peters, None; L. Mendyka, None; S. Shan, None; A. Cortez, None; W. Rigby, Bristol Myers Squibb, AbbVie; C. Burns, None; R. Noelle, None; S. Skopelja-Gardner, None.

To cite this abstract in AMA style:

Peters Z, Mendyka L, Shan S, Cortez A, Rigby W, Burns C, Noelle R, Skopelja-Gardner S. Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/immune-checkpoint-vista-regulates-type-i-interferon-ifn-i-production-and-controls-uv-light-triggered-skin-ifn-i-response/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immune-checkpoint-vista-regulates-type-i-interferon-ifn-i-production-and-controls-uv-light-triggered-skin-ifn-i-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology